Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (Cancelled).

6. (Currently amended): A compound of formula (i) or a pharmaceutically acceptable salt thereof:

$$(R^2)_m$$
 $(CH_2)_p$
 R^5
 $(R^3)_n$
 R^5
 R^{3a}
 (i)

wherein

 R^1 and R^2 independently represent hydrogen or C_{1-6} alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

 R^3 represents hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

 R^{3a} and R^{5} independently represent hydrogen or $C_{1\text{-}6}$ alkyl;

 R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n represents 1 or 2; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluoromethoxy;

or solvates thereof.

7. (Currently amended): A compound of formula (ii) or a pharmaceutically acceptable salt thereof:

$$(R^2)_m$$
 $(CH_2)_p$
 $(R^3)_n$
 $(R^3)_n$

wherein

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

 R^3 represents hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

 R^{3a} and R^{5} independently represent hydrogen or $C_{1\text{-}6}$ alkyl;

 R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n represents 1 or 2; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluromethoxy;

or solvates thereof.

8. (Currently amended): A compound of formula (iii) or a pharmaceutically acceptable salt thereof:

$$(R^2)_m$$
 $(CH_2)_p$
 $(R^4)_s$
 (iii)

wherein

 R^1 and R^2 independently represent hydrogen or $C_{1\text{-}6}$ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

 R^3 and R^4 independently represent hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

 R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n represents 1 or 2;

s represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluromethoxy;

or solvates thereof.

9. (Currently amended): A compound of formula (iv) or a pharmaceutically acceptable salt thereof:

$$(R^2)_m$$
 $(CH_2)_p$
 $(R^3)_r$
 $(R^4)_q$
 (iv)

wherein

 R^1 and R^2 independently represent hydrogen or $C_{1\text{-}6}$ alkyl;

p represents 1 or 2;

m represents an integer from 1 to 4;

 R^3 and R^4 independently represent hydrogen, halogen, cyano, -CF₃, -OCF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

 R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

q represents 1 or 2;

r represents an integer from 1 to 3; and

A represents a phenyl or pyridyl group optionally substituted by one or more halogen atoms, cyano, trifluoromethyl or trifluromethoxy;

or solvates thereof.

- 10. (Previously presented): A compound according to claim 6 which is: 4-(3-Phenylsulfonyl-1*H*-pyrrolo[3,2-*b*]pyridin-7-yl)-piperazine hydrochloride; 4-Methyl-7-piperazin-1-yl-3-phenylsulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine; 1-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-1*H*-pyrrolo[3,2-*b*] pyridine; 4-Methyl-7-piperazin-1-yl-3-(2-fluorophenyl)sulfonyl-4*H*-pyrrolo[3,2-*b*] pyridine; or a pharmaceutically acceptable salt thereof.
- 11. (Previously presented): A compound according to claim 7 which is: 7-Piperazin-1-yl-3-phenylsulfonyl-1*H*-pyrrolo[2,3-*c*] pyridine hydrochloride; 3-(2-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride; 3-(3-Fluorophenyl)sulfonyl-7-piperazin-1-yl-1*H*-pyrrolo[2,3-*c*]pyridine hydrochloride; or a pharmaceutically acceptable salt thereof.
- 12. (Previously presented): A compound according to claim 8 which is: 2-Methyl-4-piperazin-1-yl-7-phenylsulfonylquinoline hydrochloride; or a pharmaceutically acceptable salt thereof.
- 13. (Previously presented): A compound according to claim 9 which is: 4-Phenylsulfonyl-8-piperazin-1-yl quinoline;
- 4-Phenylsulfonyl-8-piperazin-1-yl-quinoline hydrochloride;
- 2-Methyl -4-phenylsulfonyl-8-piperazin-1-yl-quinoline;
- 2-Methyl-4-phenylsulfonyl-8-piperazin-1-ylquinoline hydrochloride;
- 2-Methyl-4-(2-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;
- 2-Methyl-4-(3-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride;
- 2-Methyl-4-(3-chlorophenyl)sulfonyl-8-piperazin-1-ylquinoline hydrochloride; or a pharmaceutically acceptable salt thereof.

14. (Currently amended): A pharmaceutical composition which comprises [[a]] the compound according to claim 6 and a pharmaceutically acceptable carrier or excipient.

- 15. (Currently amended): A pharmaceutical composition which comprises [[a]] the compound according to claim 7 and a pharmaceutically acceptable carrier or excipient.
- 16. (Currently amended): A pharmaceutical composition which comprises [[a]] the compound according to claim 8 and a pharmaceutically acceptable carrier or excipient.
- 17. (Currently amended): A pharmaceutical composition which comprises [[a]] the compound according to claim 9 and a pharmaceutically acceptable carrier or excipient.
- 18. (Currently amended): A method of treating <u>disease selected from the group</u> depression, anxiety, obesity and cognitive memory disorders which comprises administering a <u>safe and</u>-therapeutically effective amount, to a patient in need thereof, of [[a]] <u>the</u> compound as defined in claim 6 or a pharmaceutically acceptable salt thereof.
- 19. (Currently amended): A method of treating <u>disease selected from the group</u> depression, anxiety, obesity and cognitive memory disorders which comprises administering a <u>safe and</u>-therapeutically effective amount, to a patient in need thereof, of [[a]] <u>the</u> compound as defined in claim 7 or a pharmaceutically acceptable salt thereof.
- 20. (Currently amended): A method of treating <u>disease selected from the group</u> depression, anxiety, obesity and cognitive memory disorders which comprises administering a <u>safe and</u>-therapeutically effective amount, to a patient in need thereof, of [[a]] <u>the</u> compound as defined in claim 8 or a pharmaceutically acceptable salt thereof.

21. (Currently amended): A method of treating <u>a disease selected from the group</u> depression, anxiety, obesity and cognitive memory disorders which comprises administering a <u>safe and</u> therapeutically effective amount, to a patient in need thereof, of [[a]] <u>the</u> compound as defined in claim 9 or a pharmaceutically acceptable salt thereof.